TerminatedPhase 2

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

Stopped: See termination reason in detailed description.

United States60 participantsStarted 2006-01

Plain-language summary

The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of resistant hypertension. * A stable anti-hypertensive drug regimen for at least 30 days. Exclusion Criteria: * Sustained blood pressure greater than or equal to 180/120 mmHg. * Required use of thigh cuff for blood pressure readings. * Uncontrolled diabetes mellitus.

What they're measuring

Maximum Blood Pressure (BP) Increase

Timeframe: Baseline (Pre-Dose on Day 1 of Week 2) up to Week 12

Weighted Mean (Area Under Effect Curve [AUEC]) Blood Pressure Change

Timeframe: Baseline (Pre-Dose on Day 1 of Week 2) up to Week 12

Trial details

NCT IDNCT00272961

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-08

Results submitted2013-01-28

View on ClinicalTrials.gov More Resistant Hypertension trials